Latest news with #Claromers™
Yahoo
11-06-2025
- Business
- Yahoo
Maxwell Targets $500B Cosmetics Market with Microbiome-Friendly Antiseptics
Austin, Texas--(Newsfile Corp. - June 11, 2025) - Maxwell Biosciences, an innovator in technology that behaves like the natural immune system, announces its strategic entry into partnerships and licensing deals in the cosmetics and personal care market with its immune-inspired Claromer™ platform. The company's breakthrough Claromer™ technology is now being tested by some of the top cosmetics companies in the world. Maxwell aims to usher in a new generation of personal care products designed for today's health-conscious consumer. To view an enhanced version of this graphic, please visit: The Opportunity for Something BetterMaxwell's entry into partnerships with the cosmetics industry is about enhancing skin health and longevity at the molecular level. Inspired by the body's natural defenses, Maxwell's technology protects against harmful pathogens and nurtures the skin's healthy microbiome, ensuring a balanced and thriving ecosystem. These products will not be tested on animals. "Our mission has always been to create health for the world, safely and affordably," said J. Scotch McClure, CEO of Maxwell Biosciences. "The cosmetics space is overdue for a revolution in safety and performance. Claromers™ can deliver that—naturally, safely and without harming the skin's delicate ecosystem." Maxwell is moving forward with active collaborations with global leaders in cosmetics. Additional opportunities are now open for strategic partners. To learn more about Maxwell's Claromer™ platform for cosmetics and personal care, visit About Maxwell BiosciencesMaxwell Biosciences is a global health technology company pioneering a new category of immune-inspired small molecules called Claromers™. Designed to mimic and enhance the body's natural defenses, Claromers™ destroy pathogenic bacteria, viruses, fungi and biofilms—without harming healthy cells or the microbiome. Originally developed for critical infectious diseases, Maxwell's technology is now entering commercial deployment across cosmetics, personal care, medical coatings and biodefense. Claromers™ require no refrigeration and are highly stable in even the harshest environments. Backed by a decade of research, a robust patent portfolio and leadership with deep expertise in science, military, AI and global health, Maxwell has collaborative agreements with the US military and governments worldwide. FDA clinical trials are planned for 2026. Non-pharmaceutical commercialization begins in 2025, with pilot access with select partners already underway. Maxwell's AI-first platform enables rapid innovation against the rising threat of resistant pathogens, offering scalable, shelf-stable and microbiome-resilient solutions for a healthier planet. To learn more about Maxwell Biosciences, visit or follow us on X and LinkedIn. ContactPress@ To view the source version of this press release, please visit
Associated Press
23-04-2025
- Health
- Associated Press
Maxwell Biosciences Secures Anti-Diarrheal US Military Agreement
Maxwell's 7th signed US military agreement is for in vitro testing of Maxwell's Claromers for the treatment of diarrheal pathogens Austin, Texas--(Newsfile Corp. - April 23, 2025) - Maxwell Biosciences, a preclinical drug platform company that develops Claromers TM, synthetic small molecules that mimic and improve upon the natural immune system, today announced a new collaboration. Maxwell has entered into a Limited Purpose Cooperative Research and Development Agreement (LP-CRADA) with the U.S. Naval Medical Research Command's (NMRC) Deployment Associated Infections Division (DAID) laboratory to conduct in vitro testing of Claromers™ for treatment and prevention of diarrheal illness. This agreement marks the 7th signed U.S. military agreement for Maxwell. [ This image cannot be displayed. Please visit the source: ] To view an enhanced version of this graphic, please visit: Diarrheal diseases remain the most pervasive infectious threat to U.S. military operational readiness [ 1 ]. The majority of cases result from increasingly drug-resistant strains of bacteria causing debilitating outbreaks that cripple mission effectiveness. During Operation Iraqi Freedom (OIF), 76% of warfighters experienced diarrheal episodes. Diarrheal diseases outpaced respiratory illnesses and injuries as the top non-combat medical issue [ 2 ]. In field conditions, even a single episode of diarrhea can sideline a soldier for days, impairing unit performance and mission success. 80% of cases require antibiotics or IV fluids [ 3 ]. Chronic post-infection complications like irritable bowel syndrome (15-30% of cases) and reactive arthritis further degrade long-term readiness [ 4 ]. As antibiotic resistance continues to rise, traditional treatments are losing efficacy, making preventive options and new therapeutic approaches an urgent priority. The impact isn't limited to the battlefield: travelers, humanitarian responders and civilians in low-resource settings also face similar risks, underscoring the need for globally relevant solutions. 'This partnership isn't just about stopping pathogens; it's about keeping our forces mission-ready and preventing critical situations from going down the drain. With Claromers™, we're determined to flush out antibiotic resistance and ensure troops aren't bogged down by debilitating illnesses,' said Scotch McClure, Founder & CEO of Maxwell Biosciences. About NMRC NMRC, headquarters of Navy Medicine Research & Development, is engaged in a broad spectrum of activity from basic science in the laboratory to field studies in austere and remote areas of the world to investigations in operational environments. In support of Navy, Marine Corps, and joint U.S. warfighter health, readiness and lethality, researchers study infectious diseases, biological warfare detection and defense, combat casualty care, environmental health concerns, aerospace and undersea medicine, operational mission support and epidemiology. About DAID Part of NMRC's Operationally Relevant Infections Department, DAID focuses on the advancement of both prophylactic vaccine and immunoprophylaxis products against Campylobacter, ETEC and Shigella mediated diseases that affect the warfighter. About Maxwell Biosciences Founded in 2016, Maxwell Biosciences is a preclinical drug platform company that develops Claromers TM, synthetic small molecules that mimic and improve upon the natural immune system. Inspired by nature, these deep tech breakthrough molecules have been shown to be effective against Ebola, pan-coronavirus and pan-Influenza A (avian, swine and human) in destroying viruses, but also all tested bacteria, fungi and biofilms with a single compound, while safely preserving healthy cells. This new 'One Drug for Many Bugs' technology has been shown to be well-tolerated in lab-grown human tissues and in multiple animal studies and is shelf-stable. The compounds imitate key components of the innate immune system: humanity's greatest asset in fighting disease. Maxwell's technology is protected by numerous granted and pending patents and is led by a world-class team of scientists, military veterans and experienced life science executives. For more information, visit or follow us on X and LinkedIn. Contacts Media [email protected] Investors [email protected] Disclaimer The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government. To view the source version of this press release, please visit
